Podium to Practice: EHA 2026 – Leukemia: OPTI-AML

Podium to Practice: EHA 2026 – Leukemia: OPTI-AML

Podium to Practice: EHA 2026

Studies / Trials Discussed

S126 – OPTI-AML: PROSPECTIVE RANDOMIZED PHASE 2 TRIAL OF 28 VERSUS 14 DAY SCHEDULE OF VENETOCLAX AND AZACITIDINE FOR 2 CYCLES IN NEWLY DIAGNOSED GENOMICALLY AGNOSTIC ACUTE MYELOID LEUKEMIA PATIENTS ≥60 YEARS

Icon Chair Speaker

Chair

Dr. Brett Houston

Icon Chair Speaker

Speakers

Dr. Christopher Hillis

Dr. Sonia Cerquozzi

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

S126 – OPTI-AML: PROSPECTIVE RANDOMIZED PHASE 2 TRIAL OF 28 VERSUS 14 DAY SCHEDULE OF VENETOCLAX AND AZACITIDINE FOR 2 CYCLES IN NEWLY DIAGNOSED GENOMICALLY AGNOSTIC ACUTE MYELOID LEUKEMIA PATIENTS ≥60 YEARS
Tagged